FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

研究用のみ。 完全な免責事項 →

研究/Highlighting the gap between clinical trial outcomes and real-world effectiveness of GLP-1RAs for weight management.
研究ライブラリに戻る
GLP-1RAsliraglutidesemaglutidetirzepatide

Highlighting the gap between clinical trial outcomes and real-world effectiveness of GLP-1RAs for weight management.

May 16, 2026
Share

元の論文

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

Thomsen Reimar W et al.Diabetes, obesity & metabolism2025
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Real-World Use of GLP-1RAs: A Closer Look at Weight Loss Outcomes

Published: May 16, 2026 | Source: Diabetes, obesity & metabolism (2025) | Category: GLP-1RAs, liraglutide, semaglutide, tirzepatide

Overview

A new review published in Diabetes, Obesity & Metabolism examines the real-world effectiveness and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss. The study highlights that while GLP-1RAs show promise in clinical trials, their performance in everyday use is often less impressive due to lower adherence rates and suboptimal dosing.

Study Background

GLP-1RAs have gained prominence as effective treatments for obesity and type 2 diabetes. Clinical trials have demonstrated significant weight loss benefits with these drugs; however, translating these results into real-world settings has been challenging. Researchers sought to understand how GLP-1RA-based therapies perform in actual patient populations, focusing on liraglutide, semaglutide, and tirzepatide.

What the Research Found

The review synthesizes data from observational studies indicating that weight loss outcomes in real-world settings are generally lower than those reported in clinical trials. Adherence to GLP-1RA therapy is a significant issue, with discontinuation rates ranging between 20% and 50% within one year of starting treatment. Additionally, patients often use lower doses than recommended in clinical guidelines.

Gastrointestinal side effects such as nausea and vomiting are common among users of GLP-1RAs, aligning with findings from randomized controlled trials (RCTs). However, the review found no clear evidence suggesting an increased risk of severe adverse events like pancreatitis or pancreatic cancer. The study also notes a lack of robust data on potential associations between GLP-1RA use and eye disease or other rare conditions.

What This Means for Peptide Users

The findings suggest that while GLP-1RAs can be effective in managing weight, their real-world utility may be limited by issues like poor adherence and improper dosing. Patients should be aware of the importance of following prescribed treatment regimens to achieve optimal results. Healthcare providers need to monitor patients closely for side effects and ensure they are receiving appropriate doses.

Limitations and Caveats

The review relies heavily on observational studies, which can introduce biases that clinical trials aim to minimize through strict protocols. The lack of control over patient adherence in real-world settings complicates the interpretation of effectiveness data. Moreover, the absence of long-term follow-up data means potential risks associated with prolonged use remain unclear.

How This Compares to Previous Research

Earlier studies have also noted discrepancies between trial outcomes and real-world performance for GLP-1RAs but often lacked detailed insights into adherence issues or dosing patterns. The current review provides a more comprehensive analysis by integrating recent observational data, offering a clearer picture of the practical challenges associated with these therapies.

Our Analysis

PeptideVault views this review as an important contribution to understanding the real-world efficacy and safety profile of GLP-1RAs. While it highlights significant gaps between clinical trial results and everyday use, it also identifies critical areas for future research, such as investigating the impact of discontinuing treatment and exploring long-term outcomes in diverse patient populations.

Key Takeaways

  • Real-world effectiveness is often lower than clinical trials due to poor adherence and suboptimal dosing.
  • Gastrointestinal side effects are common but severe adverse events like pancreatitis or cancer do not appear more frequent.
  • Further research is needed on long-term safety, discontinuation impacts, and cost-effectiveness in real-world settings.

Original Source

Citation: Thomsen Reimar W, Mailhac Aurélie, Løhde Julie B et al. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.. Diabetes, obesity & metabolism. DOI: 10.1111/dom.16364

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。